Alexandria Real Estate Equities Inc. - ARE STOCK NEWS

Alexandria Real Estate Equities, Inc. has been named one of Newsweek's Most Trustworthy Companies in America for the second year, recognized for customer, investor, and employee trust. The company has strong tenant relationships with leading life science firms, driving 76% of leasing activity from existing tenants. Alexandria focuses on creating value for investors, achieving a TSR of 1,512% since its IPO. It has also received multiple awards for transparent reporting and sustainability practices. The company prioritizes employee well-being, offering competitive compensation, benefits, and career development opportunities. Alexandria's commitment to social responsibility is evident through initiatives like OneFifteen for addiction recovery and support for the Navy SEAL Foundation.

Alexandria Real Estate Equities, Inc. announces insitro's 6-year lease extension for laboratory space at the Alexandria Center for Advanced Technologies in South San Francisco. This renewal highlights insitro's commitment to AI-driven drug discovery and development, emphasizing the importance of specialized laboratory space for AI-enhanced R&D in life sciences.

Alexandria Real Estate Equities, Inc. (ARE) declares a quarterly cash dividend of $1.27 per common share for Q1 2024, representing a 5% increase over the previous year. The company plans to reinvest $2.1 billion into new development projects while maintaining a low FFO payout ratio.

Alexandria Real Estate Equities, Inc. announces a 10-year lease extension with Takeda Pharmaceutical Company Limited at the Alexandria Center® at Kendall Square mega campus. The extension demonstrates Takeda's commitment to Alexandria's Labspace® infrastructure, showcasing strong rental rate increases and a focus on advancing innovative medicines.

Alexandria Real Estate Equities, Inc. (ARE) will host a conference call and webcast to discuss its first quarter 2024 operating and financial results on April 23, 2024. The company will release the results on April 22, 2024, after the market closes. Participants can join the call by dialing (833) 366-1125 (U.S.) or (412) 902-6738 and accessing the webcast on the company's website. A replay will be available until April 30, 2024, accessible by dialing (877) 344-7529 (U.S.) or (412) 317-0088.

Alexandria Real Estate Equities, Inc. announced AstraZeneca's $300 million investment in a cell therapy manufacturing facility at the Alexandria Center for Life Science - Shady Grove mega campus. The facility will support AstraZeneca's biomanufacturing of T-cell therapies, creating over 150 jobs. This investment underscores Alexandria's leadership in the Maryland life science ecosystem and highlights the company's commitment to innovation and growth.

Alexandria Real Estate Equities, Inc. (ARE) has announced a public offering of $400,000,000 aggregate principal amount of 5.250% senior notes due 2036 and $600,000,000 aggregate principal amount of 5.625% senior notes due 2054. The notes will be unsecured obligations of the Company and fully and unconditionally guaranteed by Alexandria Real Estate Equities, L.P., an indirectly 100% owned subsidiary of the Company. The offering is led by a group of joint book-running managers and co-managers. The senior notes due 2036 were priced at 99.787% of the principal amount with a yield to maturity of 5.271%, and the senior notes due 2054 were priced at 99.943% of the principal amount with a yield to maturity of 5.627%.

Alexandria Real Estate Equities, Inc. (ARE) has announced the commencement of an underwritten public offering of two tranches of senior notes. The notes will be unsecured obligations of the company and fully guaranteed by an indirectly owned subsidiary. The net proceeds from the offering will be used for general working capital, corporate purposes, and the reduction of outstanding debts. The offering is being made pursuant to an effective registration statement on Form S-3 previously filed with the Securities and Exchange Commission.

Alexandria Real Estate Equities, Inc. (ARE) announced financial results for Q4 and full year 2023. The company achieved a 13% revenue growth in Q4, with total revenues reaching $757.2 million. However, the net loss attributable to common stockholders was $91.9 million, leading to a diluted loss per share of $0.54. On a positive note, the company celebrated its 30th anniversary and has seen significant shareholder returns, outperforming major indices. Alexandria maintains a strong balance sheet and high-quality client base, with 75% of annual rental revenue coming from mega campuses and 52% from investment-grade tenants. The company also demonstrated strong tenant collections, with 99.9% of 4Q23 rents and receivables collected as of January 29, 2024. Additionally, Alexandria reported solid leasing volume and rental rate increases, as well as a flexible balance sheet with significant liquidity. The company's net operating income grew by 11.3% in Q4 2023, and a consistent dividend strategy reflects a 4.0% dividend yield as of December 31, 2023. Alexandria also executed a value harvesting and asset recycling strategy, completing $1.4 billion in dispositions and partial interest sales in 2023.